Figure 2.

Impact of TdLNs on Tumor Recurrence and Immunotherapy Response in Advanced Stage Tumor Models

(A) The experimental schedule. Resection of TdLNs did not accelerate localized secondary tumor (mimicking recurrent tumor) development in both CT26 and MC38 subcutaneous tumor models. However, systemic deletion of T cells significantly accelerated secondary tumor development in both tumor models (n = 8–10 in each group, both individual and summarized curves were shown, t tests were performed between the TdLN resected and T cell-depleted groups, data were displayed as means ± SEMs, t test was performed between the TdLN(−) and TdLN(−) T cell-depleted groups, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).

(B) Systemic depletion of T cells, but not TdLN resection, led to a shorter survival time of mice owing to secondary tumor development (n = 8–10 in each group, log rank test between indicated groups, ∗∗p < 0.01).

(C) Response to anti-4-1BB and anti-PD-1 treatment was tested in localized secondary tumors with or without TdLNs. Anti-4-1BB and anti-PD-1 treatments suppressed secondary tumor growth in both TdLN intact and resected mice (n = 5 in each group, data were displayed as means ± SEMs).

See also Figures S1, S2, and S4, and Table S1.